Pear Therapeutics

A new exploratory collaboration with Ironwood Pharmaceuticals comes just a couple weeks after the digital therapeutics startup ended a commercialization relationship with Novartis' Sandoz.

The pharma's Sandoz division will be handing commercialization of reSET, reSET-O and future therapies back to Pear over the course of a transition period.

Panelists at MassBio's Digital Health Impact event yesterday talk the pros and cons of the West Coast's tech culture and the East Coast's clinical tradition. 

CEO and President Dr. Corey McCann said that Somryst, a digital treatment for chronic insomnia and depression, is the first software as a medical device product to be submitted through the regulator's pilot pathway. 

Development of the Pear-006 digital therapeutic is a joint collaboration with Novartis.

Commitment to digital health varies across today’s leading pharmas, and many stakeholders are still waiting for the novel treatments to prove themselves with evidence and commercialization success.

The company has plans to work on new, streamlined design systems for the future. 

The latest funding was led by Temasek, with participation from Novartis, 5AM Ventures, Arboretum Ventures, Jazz Partners, The Bridge Builders Collaborative and EDBI. 

The prescription digital therapeutic will give users interactive therapy lessons to be use by patients under a clinician's supervision.   

A new innovation center called the Biome and numerous internal efforts paint a picture of a digital-focused game plan.